Avalo Therapeutics, Inc.
Avalo Therapeutics, Inc. (AVTX): 5 pipeline candidates · ~14 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
13.8 months
D/E 0.46 · 0% dilution
Lead: Phase 2
5 candidates
N/A
0 buys · 29 sells (180d)
A transparent, data-derived signal for Avalo Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$750.6M
Cash
$25.3M
Quarterly Burn
$17.7M
Runway
13.8 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| abdakibart | Phase 2 |
| AVTX-009 | Phase 2 |
| avtx-009 regimen 1 | Phase 2 |
| avtx-009 regimen 2 | Phase 2 |
| AVTX-913 | Preclinical |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
96
Total value held
$423.3M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 2,879,481 | $43.0M |
| caligan partners lp | 1,635,023 | $24.4M |
| bvf inc/il | 1,632,845 | $24.4M |
| vanguard capital management llc | 1,439,388 | $21.5M |
| affinity asset advisors, llc | 1,340,840 | $20.0M |
| logos global management lp | 1,300,000 | $19.4M |
| caption management, llc | 1,086,700 | $16.2M |
| farallon capital management llc | 916,000 | $13.7M |
| rtw investments, lp | 856,962 | $12.8M |
| adage capital partners gp, l.l.c. | 854,000 | $12.8M |
Showing top 10 of 96 institutional holders of Avalo Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Avalo Therapeutics, Inc.'s pipeline?
Avalo Therapeutics, Inc. (AVTX) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Avalo Therapeutics, Inc.'s lead drug candidate?
Avalo Therapeutics, Inc.'s most advanced tracked candidate is abdakibart (Phase 2) for hidradenitis suppurativa.
What is Avalo Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Avalo Therapeutics, Inc. has approximately 13.8 months of cash runway.
What is Avalo Therapeutics, Inc.'s market capitalization?
Avalo Therapeutics, Inc.'s market capitalization is approximately $750.6M.
Who is the CEO of Avalo Therapeutics, Inc.?
Dr. Garry A. Neil M.D. is the chief executive officer of Avalo Therapeutics, Inc. (AVTX).
Get the full picture on Avalo Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.